These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 21120364)

  • 61. In Vitro and In Vivo Trypanosomicidal Action of Novel Arylimidamides against Trypanosoma cruzi.
    Guedes-da-Silva FH; Batista DG; Meuser MB; Demarque KC; Fulco TO; Araújo JS; Da Silva PB; Da Silva CF; Patrick DA; Bakunova SM; Bakunov SA; Tidwell RR; Oliveira GM; Britto C; Moreira OC; Soeiro MN
    Antimicrob Agents Chemother; 2016 Apr; 60(4):2425-34. PubMed ID: 26856830
    [TBL] [Abstract][Full Text] [Related]  

  • 62. An update on benznidazole for the treatment of patients with Chagas disease.
    Thakare R; Dasgupta A; Chopra S
    Drugs Today (Barc); 2018 Jan; 54(1):15-23. PubMed ID: 29569658
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Memory impairment in chronic experimental Chagas disease: Benznidazole therapy reversed cognitive deficit in association with reduction of parasite load and oxidative stress in the nervous tissue.
    Vilar-Pereira G; Castaño Barrios L; Silva AAD; Martins Batista A; Resende Pereira I; Cruz Moreira O; Britto C; Mata Dos Santos HA; Lannes-Vieira J
    PLoS One; 2021; 16(1):e0244710. PubMed ID: 33400707
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Benznidazole and Posaconazole in Eliminating Parasites in Asymptomatic T. Cruzi Carriers: The STOP-CHAGAS Trial.
    Morillo CA; Waskin H; Sosa-Estani S; Del Carmen Bangher M; Cuneo C; Milesi R; Mallagray M; Apt W; Beloscar J; Gascon J; Molina I; Echeverria LE; Colombo H; Perez-Molina JA; Wyss F; Meeks B; Bonilla LR; Gao P; Wei B; McCarthy M; Yusuf S;
    J Am Coll Cardiol; 2017 Feb; 69(8):939-947. PubMed ID: 28231946
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Combination Chemotherapy with Suboptimal Doses of Benznidazole and Pentoxifylline Sustains Partial Reversion of Experimental Chagas' Heart Disease.
    Vilar-Pereira G; Resende Pereira I; de Souza Ruivo LA; Cruz Moreira O; da Silva AA; Britto C; Lannes-Vieira J
    Antimicrob Agents Chemother; 2016 Jul; 60(7):4297-309. PubMed ID: 27161638
    [TBL] [Abstract][Full Text] [Related]  

  • 66. A functional assay using human whole blood and flow cytometry analysis to evaluate cytotoxicity and immunomodulatory effect of anti-Trypanosoma cruzi drugs.
    Lopes MEASA; Ribeiro JM; Teixeira-Carvalho A; Murta SMF; Souza-Fagundes EM
    Exp Parasitol; 2023 Apr; 247():108490. PubMed ID: 36809831
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Antiparasitic Effect of Vitamin B12 on Trypanosoma cruzi.
    Ciccarelli AB; Frank FM; Puente V; Malchiodi EL; Batlle A; Lombardo ME
    Antimicrob Agents Chemother; 2012 Oct; 56(10):5315-20. PubMed ID: 22869565
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [Trypanosoma cruzi strains resistant to benznidazole occurring in Colombia].
    Mejía-Jaramillo AM; Fernández GJ; Montilla M; Nicholls RS; Triana-Chávez O
    Biomedica; 2012 Jun; 32(2):196-205. PubMed ID: 23242293
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Phenotypic diversity and drug susceptibility of Trypanosoma cruzi TcV clinical isolates.
    Quebrada Palacio LP; González MN; Hernandez-Vasquez Y; Perrone AE; Parodi-Talice A; Bua J; Postan M
    PLoS One; 2018; 13(9):e0203462. PubMed ID: 30183775
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Ruthenium complex with benznidazole and nitric oxide as a new candidate for the treatment of chagas disease.
    Sesti-Costa R; Carneiro ZA; Silva MC; Santos M; Silva GK; Milanezi C; da Silva RS; Silva JS
    PLoS Negl Trop Dis; 2014 Oct; 8(10):e3207. PubMed ID: 25275456
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Trypanosoma cruzi-Specific T-Cell Responses to Monitor Treatment Efficacy in Chronic Chagas Disease.
    Albareda MC; Natale MA; Cesar GL; Castro Eiro MD; Alvarez MG; Laucella SA
    Methods Mol Biol; 2019; 1955():339-348. PubMed ID: 30868539
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Treatment with benznidazole during the chronic phase of experimental Chagas' disease decreases cardiac alterations.
    Garcia S; Ramos CO; Senra JF; Vilas-Boas F; Rodrigues MM; Campos-de-Carvalho AC; Ribeiro-Dos-Santos R; Soares MB
    Antimicrob Agents Chemother; 2005 Apr; 49(4):1521-8. PubMed ID: 15793134
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Assessment of a combined treatment with a therapeutic vaccine and benznidazole for the Trypanosoma cruzi chronic infection.
    Prochetto E; Bontempi I; Rodeles L; Cabrera G; Vicco M; Cacik P; Pacini MF; Pérez Gianeselli M; Pérez AR; Marcipar I
    Acta Trop; 2022 May; 229():106334. PubMed ID: 35101415
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Comparative studies of drug susceptibility of five strains of Trypanosoma cruzi in vivo and in vitro.
    Neal RA; van Bueren J
    Trans R Soc Trop Med Hyg; 1988; 82(5):709-14. PubMed ID: 3075357
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Chemotherapy of Chagas' disease: status and new developments.
    Cerecetto H; González M
    Curr Top Med Chem; 2002 Nov; 2(11):1187-213. PubMed ID: 12171581
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Combination therapy with benznidazole and doxycycline shows no additive effect to monotherapy with benznidazole in mice infected with the VL-10 strain of the Trypanosoma cruzi.
    Carneiro ACA; Costa GP; Ferreira CS; Ramos IPR; Sarandy MM; Leite ALJ; Menezes APJ; Silva BM; Nogueira KOPC; Carvalho ACC; Gonçalves RV; Talvani A
    Int J Cardiol; 2020 Jan; 299():243-248. PubMed ID: 31353153
    [TBL] [Abstract][Full Text] [Related]  

  • 77. An in vitro iron superoxide dismutase inhibitor decreases the parasitemia levels of Trypanosoma cruzi in BALB/c mouse model during acute phase.
    Olmo F; Urbanová K; Rosales MJ; Martín-Escolano R; Sánchez-Moreno M; Marín C
    Int J Parasitol Drugs Drug Resist; 2015 Dec; 5(3):110-6. PubMed ID: 26236582
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Acute Chagas outbreaks: molecular and biological features of Trypanosoma cruzi isolates, and clinical aspects of acute cases in Santander, Colombia.
    Díaz ML; Leal S; Mantilla JC; Molina-Berríos A; López-Muñoz R; Solari A; Escobar P; González Rugeles CI
    Parasit Vectors; 2015 Nov; 8():608. PubMed ID: 26612724
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Impact of levamisole in co-administration with benznidazole on experimental Chagas disease.
    Rocha Simões-Silva M; Brandão Peres R; Britto C; Machado Cascabulho C; de Melo Oliveira G; Nefertiti da Gama A; França da Silva C; Lima da Costa K; Finamore Araújo P; Diego de Souza Campos J; Meuser Batista M; Cristina Demarque K; da Cruz Moreira O; de Nazaré Correia Soeiro M
    Parasitology; 2019 Jul; 146(8):1055-1062. PubMed ID: 31046850
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Benznidazole, itraconazole and their combination in the treatment of acute experimental chagas disease in dogs.
    Cunha ELA; Torchelsen FKVDS; Cunha LM; de Oliveira MT; Fonseca KDS; Vieira PMA; Carneiro CM; de Lana M
    Exp Parasitol; 2019 Sep; 204():107711. PubMed ID: 31254494
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.